Zoetis completes acquisition of Nexvet Biophrma


Published:

Zoetis Inc., manufacturer of veterinary vaccines and medicines for veterinarians, livestock producers, farmers, and pet owners, announced the completion of its $85 million acquisition of Nexvet Biopharma, a Tullamore, Ireland-based company that manufactures monoclonal antibodies (mAb) for companion animal pain management.

The annual market for chronic pain management therapies for companion animals is valued at $400 million annually, according to Zoetis, whose global headquarters for research and development are in Kalamazoo County, Mich.

Monoclonal antibodies, produced in a laboratory from a single clone of cells or a single cell line, have great potential in the field of pain-management for domestic animals, said Zoetis in a statement.

Nexvet comes with two pipeline products: ranevetmab, an mAb targeting nerve-growth factor, which is being investigated to treat chronic pain associated with osteoarthritis in dogs, and frunevetmab, which treats the same disease in cats.

 

Edit Module
Edit ModuleShow Tags

Archive »Read More

Veterinary managers receive credential program scholarship

Support veterinary clients’ supplemental endeavors

The clinician-client partnership is vital when pet owners wish to help their pets achieve optimum health with supplements.

AVMA Future Leaders develop positive work environment resources, tools

"CPR to Revive Your Veterinary Team" aims to help create a healthy veterinary workplace culture.
Edit Module
Edit Module
Edit ModuleEdit ModuleShow Tags Edit Module
Edit Module Edit Module
Edit ModuleShow Tags

Events


Show More...
Edit Module
Edit Module